Cargando…
The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity
PURPOSE: Stereotactic radiation therapy (SRT) enables focused, short course, high dose per fraction radiation delivery to brain tumors that are less ideal for single fraction treatment because of size, shape, or close proximity to sensitive structures. We sought to identify optimal SRT treatment reg...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605319/ https://www.ncbi.nlm.nih.gov/pubmed/29114607 http://dx.doi.org/10.1016/j.adro.2017.05.008 |
_version_ | 1783264966573293568 |
---|---|
author | Jimenez, Rachel B. Alexander, Brian M. Mahadevan, Anand Niemierko, Andrzej Rajakesari, Selvan Arvold, Nils D. Floyd, Scott R. Oh, Kevin S. Loeffler, Jay S. Shih, Helen A. |
author_facet | Jimenez, Rachel B. Alexander, Brian M. Mahadevan, Anand Niemierko, Andrzej Rajakesari, Selvan Arvold, Nils D. Floyd, Scott R. Oh, Kevin S. Loeffler, Jay S. Shih, Helen A. |
author_sort | Jimenez, Rachel B. |
collection | PubMed |
description | PURPOSE: Stereotactic radiation therapy (SRT) enables focused, short course, high dose per fraction radiation delivery to brain tumors that are less ideal for single fraction treatment because of size, shape, or close proximity to sensitive structures. We sought to identify optimal SRT treatment regimens for maximizing local control while minimizing morbidity. METHODS AND MATERIALS: We performed a retrospective review of patients treated with SRT for solid brain metastases using variable dose schedules between 2001 and 2011 at 3 academic hospitals. Endpoints included (1) local control, (2) acute toxicity (Common Toxicity Criteria for Adverse Events v3.0), and (3) symptomatic radionecrosis. Kaplan-Meier and a competing risks methodology were used to estimate the actuarial rate of local failure and assess the association of clinical and treatment covariates with time to local failure. RESULTS: A total of 156 patients was identified. Common tumor histologies included breast (21%), non-small cell lung (32%), melanoma (22%), small cell lung (9%), and renal cell carcinoma (6%). The majority of lesions were supratentorial (57%). Median target volume was 3.99 mL (range, 0.04-58.42). Median total SRT dose was 25 Gy (range, 12-36), median fractional dose was 5 Gy (range, 2.5-11), and median number of fractions was 5 (range, 2-10). Cumulative incidence of local progression at 3, 6, 12, 18, and 24 months was 11%, 22%, 29%, 34%, and 36%. Total prescription dose was the only factor significantly associated with time to local progression on univariate (P = .02) and multivariable analysis (P = .01, adjusted hazards ratio, 0.87). Five patients experienced seizures within 10 days of SRT and 5 patients developed radionecrosis. All patients with documented radionecrosis received prior radiation to the index lesion. CONCLUSIONS: Our series of SRT for brain metastases found total prescription dose to be the only factor associated with local control. Both acute and long-term toxicity events from SRT were modest. |
format | Online Article Text |
id | pubmed-5605319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-56053192017-11-07 The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity Jimenez, Rachel B. Alexander, Brian M. Mahadevan, Anand Niemierko, Andrzej Rajakesari, Selvan Arvold, Nils D. Floyd, Scott R. Oh, Kevin S. Loeffler, Jay S. Shih, Helen A. Adv Radiat Oncol Scientific Article PURPOSE: Stereotactic radiation therapy (SRT) enables focused, short course, high dose per fraction radiation delivery to brain tumors that are less ideal for single fraction treatment because of size, shape, or close proximity to sensitive structures. We sought to identify optimal SRT treatment regimens for maximizing local control while minimizing morbidity. METHODS AND MATERIALS: We performed a retrospective review of patients treated with SRT for solid brain metastases using variable dose schedules between 2001 and 2011 at 3 academic hospitals. Endpoints included (1) local control, (2) acute toxicity (Common Toxicity Criteria for Adverse Events v3.0), and (3) symptomatic radionecrosis. Kaplan-Meier and a competing risks methodology were used to estimate the actuarial rate of local failure and assess the association of clinical and treatment covariates with time to local failure. RESULTS: A total of 156 patients was identified. Common tumor histologies included breast (21%), non-small cell lung (32%), melanoma (22%), small cell lung (9%), and renal cell carcinoma (6%). The majority of lesions were supratentorial (57%). Median target volume was 3.99 mL (range, 0.04-58.42). Median total SRT dose was 25 Gy (range, 12-36), median fractional dose was 5 Gy (range, 2.5-11), and median number of fractions was 5 (range, 2-10). Cumulative incidence of local progression at 3, 6, 12, 18, and 24 months was 11%, 22%, 29%, 34%, and 36%. Total prescription dose was the only factor significantly associated with time to local progression on univariate (P = .02) and multivariable analysis (P = .01, adjusted hazards ratio, 0.87). Five patients experienced seizures within 10 days of SRT and 5 patients developed radionecrosis. All patients with documented radionecrosis received prior radiation to the index lesion. CONCLUSIONS: Our series of SRT for brain metastases found total prescription dose to be the only factor associated with local control. Both acute and long-term toxicity events from SRT were modest. Elsevier 2017-06-06 /pmc/articles/PMC5605319/ /pubmed/29114607 http://dx.doi.org/10.1016/j.adro.2017.05.008 Text en © 2017 The Authors on behalf of the American Society for Radiation Oncology http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Scientific Article Jimenez, Rachel B. Alexander, Brian M. Mahadevan, Anand Niemierko, Andrzej Rajakesari, Selvan Arvold, Nils D. Floyd, Scott R. Oh, Kevin S. Loeffler, Jay S. Shih, Helen A. The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity |
title | The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity |
title_full | The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity |
title_fullStr | The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity |
title_full_unstemmed | The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity |
title_short | The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity |
title_sort | impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605319/ https://www.ncbi.nlm.nih.gov/pubmed/29114607 http://dx.doi.org/10.1016/j.adro.2017.05.008 |
work_keys_str_mv | AT jimenezrachelb theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT alexanderbrianm theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT mahadevananand theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT niemierkoandrzej theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT rajakesariselvan theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT arvoldnilsd theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT floydscottr theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT ohkevins theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT loefflerjays theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT shihhelena theimpactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT jimenezrachelb impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT alexanderbrianm impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT mahadevananand impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT niemierkoandrzej impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT rajakesariselvan impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT arvoldnilsd impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT floydscottr impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT ohkevins impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT loefflerjays impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity AT shihhelena impactofdifferentstereotacticradiationtherapyregimensforbrainmetastasesonlocalcontrolandtoxicity |